204 related articles for article (PubMed ID: 30683455)
1. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database.
Poprach A; Rumanova K; Lakomý R; Chloupková R; Stanik M; Pokrivcak T; Kiss I; Slaby O; Studentova H; Melichar B; Juracek J; Fiala O; Kopecky J; Kopeckova K; Zemanova M; Buchler T
Urol Oncol; 2019 Apr; 37(4):294.e1-294.e8. PubMed ID: 30683455
[TBL] [Abstract][Full Text] [Related]
2. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
Buti S; Bersanelli M; Maines F; Facchini G; Gelsomino F; Zustovich F; Santoni M; Verri E; De Giorgi U; Masini C; Morelli F; Vitale MG; Sava T; Prati G; Librici C; Fraccon AP; Fornarini G; Maruzzo M; Leonardi F; Caffo O
Clin Genitourin Cancer; 2017 Aug; 15(4):e609-e614. PubMed ID: 28108284
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
4. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
5. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
8. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
[TBL] [Abstract][Full Text] [Related]
9. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
10. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Chrom P; Stec R; Semeniuk-Wojtas A; Bodnar L; Spencer NJ; Szczylik C
Clin Genitourin Cancer; 2016 Oct; 14(5):457-464. PubMed ID: 26980234
[TBL] [Abstract][Full Text] [Related]
11. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
13. Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.
Xue Z; Tang S; Ou J; Fang Y; Qiu M; Hong K; Tian X; Zhang H; Liu C; Ma L; Zhang S
World J Urol; 2024 May; 42(1):364. PubMed ID: 38819448
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
15. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC; Alan Ö; Başoğlu Tüylü T; Akın Telli T; Arıkan R; Çiçek FC; Ercelep Ö; Öztürk MA; Alsan Çetin İ; Ergelen R; Tinay İ; Akgül Babacan N; Kaya S; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jul; 26(5):1147-1155. PubMed ID: 31793376
[TBL] [Abstract][Full Text] [Related]
17. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.
Silagy AW; Flynn J; Mano R; Blum KA; Marcon J; DiNatale RG; Sanchez A; Carlo MI; Motzer RJ; Coleman JA; Russo P; Ostrovnaya I; Chen YB; Hakimi AA
Urol Oncol; 2019 Nov; 37(11):811.e9-811.e16. PubMed ID: 31521530
[TBL] [Abstract][Full Text] [Related]
20. The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials.
Sella A; Wang K; Sella T
Clin Genitourin Cancer; 2016 Oct; 14(5):415-419. PubMed ID: 27105724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
